BCM
KDNY

Burrage Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Burrage Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,180
Closed -$330K – 31
2020
Q3 		$330K Hold
27,180
– – 0.26% 25
2020
Q2 		$314K Hold
27,180
– – 0.22% 25
2020
Q1 		$363K Hold
27,180
– – 0.36% 29
2019
Q4 		$160K Buy
+27,180
New +$148K 0.11% 29

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Burrage Capital Management's KDNY Position: Q4 2020 in Review

Burrage Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2020, closing a stake of 27,180 shares — an estimated $330K sold.

Burrage Capital Management first reported a position in KDNY in Q4 2019 and held it in 4 quarters. The position peaked at $363K in Q1 2020. 77 funds tracked by Wall St. Rank hold KDNY as of Q4 2020.

  • Burrage Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Burrage Capital Management sold 27,180 Chinook Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $330K.
  • Burrage Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Burrage Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $363K in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Burrage Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.